Wednesday, May 6, 2026
ADVT 
International

Trump plans to sign an order requiring colleges to prove they don't consider race in admissions

Darpan News Desk The Canadian Press, 07 Aug, 2025 10:43 AM
  • Trump plans to sign an order requiring colleges to prove they don't consider race in admissions

President Donald Trump plans to sign an executive order requiring colleges to submit data to prove they do not consider race in admissions, according to a fact sheet shared by the White House ahead of the Thursday signing.


In 2023, the Supreme Court ruled against the use of affirmative action in admissions but said colleges may still consider how race has shaped students’ lives if applicants share that information in their admissions essays. 


Trump's Republican administration is accusing colleges of using personal statements and other proxies to consider race.


The executive order is similar to parts of settlement agreements the administration negotiated with Brown University and Columbia University, restoring their federal research funding. The universities agreed to give the government data on the race, grade point average and standardized test scores of applicants, admitted students and enrolled students.

The schools also agreed to an audit by the government and to release admissions statistics to the public.


Conservatives have argued that despite the Supreme Court ruling, colleges have continued to consider race through proxy measures. But in the first year of admissions after the ruling, no clear pattern emerged in how colleges' diversity changed. Results varied dramatically from one campus to the next.


Some schools, such as the Massachusetts Institute of Technology and Amherst College, saw steep drops in the percentage of Black students in their incoming classes. But at other elite, selective schools such as Yale, Princeton and the University of Virginia, the changes were less than a percentage point year to year. 

Picture Courtesy: AP Photo/Alex Brandon

MORE International ARTICLES

Getting ready for the gong show: Trump v. Biden II

Getting ready for the gong show: Trump v. Biden II
It's the sequel to last month's debate horror show between Donald Trump and Joe Biden, an invective-laced 90 minutes that laid bare the depths to which political discourse can sink in an American election year.

Getting ready for the gong show: Trump v. Biden II

US overdose deaths appear to rise amid coronavirus pandemic

US overdose deaths appear to rise amid coronavirus pandemic
Davidson lost his job. He started staying home alone in his apartment near Georgetown, Kentucky — depressed and yearning for his recovery support group that had stopped gathering in person, said his cousin Melanie Wyatt.

US overdose deaths appear to rise amid coronavirus pandemic

Pfizer: Mid-November earliest it can seek virus vaccine OK

Pfizer: Mid-November earliest it can seek virus vaccine OK
Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25.

Pfizer: Mid-November earliest it can seek virus vaccine OK

UN: Europe's pandemic restrictions are absolutely necessary

UN: Europe's pandemic restrictions are absolutely necessary
In a meda briefing on Thursday, Dr. Hans Kluge warned that even more drastic steps might be needed in such “unprecedented times.”

UN: Europe's pandemic restrictions are absolutely necessary

Out and about again: Queen Elizabeth in visit with William

Out and about again: Queen Elizabeth in visit with William
The queen unveiled a plaque to officially open the new 30 million-pound ($39 million) Energetics Analysis Centre, used by scientists for counter-terrorist work.

Out and about again: Queen Elizabeth in visit with William

Extra safety scrutiny planned as virus vaccine worries grow

Extra safety scrutiny planned as virus vaccine worries grow
The poll from The Associated Press-NORC Center for Public Affairs Research found only 46% of Americans want a COVID-19 vaccine and another 29% are unsure.

Extra safety scrutiny planned as virus vaccine worries grow